Dexcom said worldwide revenue for the quarter ended June 30, 2025 grew 15% on a reported basis to $1.157 billion. On an organic basis, revenue grew 15%, and Q2 2024 revenue was $1.004 billion.

1. 01

   Dexcom said worldwide revenue for the quarter ended June 30, 2025 grew 15% on a reported basis to $1.157 billion. On an organic basis, revenue grew 15%, and Q2 2024 revenue was $1.004 billion.

2. 02

   The company said GAAP operating income for Q2 2025 was $212.6 million, or 18.4% of revenue, and GAAP net income was $179.8 million, or $0.45 per diluted share. For Q2 2024, operating income was $158.0 million and net income was $143.5 million, or $0.35 per diluted share.

3. 03

   Dexcom raised its fiscal 2025 revenue guidance to $4.600 to $4.625 billion, representing 14 to 15% growth, and reiterated its guidance for Non-GAAP gross profit margin of approximately 62%, Non-GAAP operating margin of approximately 21%, and Adjusted EBITDA margin of approximately 30%.

4. 04

   The company said on July 25, 2025 the Board appointed Jacob S. Leach, age 47, as President and Chief Executive Officer effective January 1, 2026. Kevin R. Sayer will assume the role of Executive Chairman effective the same date, and the Board increased its size to ten directors.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.